RTI Surgical Evolves Into Evergen
RTI Surgical rebrands as Evergen, emphasizing CDMO leadership in regenerative medicine biomaterials.
RTI Surgical has rebranded itself as Evergen, signaling a strategic transformation into a premier CDMO in regenerative medicine. This evolution follows the successful acquisitions of Cook Biotech and Collagen Solutions, solidifying Evergen as the only CDMO capable of offering both allograft and xenograft biomaterials at scale.
The new identity reflects Evergen's commitment to advancing patient-centered innovations. CEO Olivier Visa emphasized the company’s focus on flexible, high-quality solutions to meet diverse therapeutic needs, while Chief People Officer Kim Spooner highlighted the unified culture driving Evergen's growth and its vision for the future.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion